It could be both. A response at 200mg and an out licensing deal. I think they want to out-license for non-cancer indications. I think plasma levels are already high enough for non-cancer indication. I really would like them to look at lux in combination with Ven at 300mg or higher for AML or B-cell cancers. I think one of their greatest mistakes is trying to find monotherapy efficacy for both Lux and Tusp. They finally are on the right track with TUSP. Do they extend that to Lux? Hopefully. Also, at some point I think LUX, TUSP, VEN combination could yield very interesting data.
Ven dramatically lowers the IC50 of Lux in B-cell cancers in vitro. APTO knows this from Druker's work with plasma samples. USE IT!
News 
Market Data 
Discover 
